See more : SUS Co.,Ltd. (6554.T) Income Statement Analysis – Financial Results
Complete financial analysis of CannaPharmaRX, Inc. (CPMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CannaPharmaRX, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Chongqing Jianshe Vehicle System Co., Ltd. (200054.SZ) Income Statement Analysis – Financial Results
- Life360, Inc. (360.AX) Income Statement Analysis – Financial Results
- Erbud S.A. (ERB.WA) Income Statement Analysis – Financial Results
- Akastor ASA (AKRYY) Income Statement Analysis – Financial Results
- UNIQA Insurance Group AG (UN9.DE) Income Statement Analysis – Financial Results
CannaPharmaRX, Inc. (CPMD)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cannapharmarx.com
About CannaPharmaRX, Inc.
CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 620.00K | 0.00 |
| Cost of Revenue | 65.56K | 294.93K | 14.36K | 128.51K | 129.04K | 0.00 | 0.00 | 0.00 | 12.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 490.00K | 0.00 |
| Gross Profit | -65.56K | -294.93K | -14.36K | -128.51K | -129.04K | 0.00 | 0.00 | 0.00 | -12.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 130.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.97% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 589.78K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 590.00K | 0.00 |
| General & Administrative | 1.04M | 4.91M | 2.61M | 4.51M | 2.85M | 532.77K | 6.63K | 1.00M | 11.06M | 1.44M | 80.31K | 89.57K | 97.10K | 91.39K | 93.56K | 200.33K | 111.78K | 0.00 | 2.93M | 10.00K |
| Selling & Marketing | 243.17K | 300.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.28M | 4.91M | 2.61M | 4.51M | 2.85M | 532.77K | 6.63K | 1.00M | 11.06M | 1.44M | 80.31K | 89.57K | 97.10K | 91.39K | 93.56K | 200.33K | 111.78K | 76.12K | 2.93M | 10.00K |
| Other Expenses | 233.79K | 402.39K | 2.71K | 128.51K | 129.04K | 63.00 | 0.00 | 4.06K | 399.03K | 2.53M | 0.00 | 0.00 | 0.00 | -1.09M | 227.48K | 0.00 | 7.01M | -87.13K | 880.00K | 0.00 |
| Operating Expenses | 1.58M | 5.21M | 2.62M | 4.64M | 2.98M | 532.77K | 6.63K | 1.00M | 11.46M | 2.03M | 80.31K | 89.57K | 97.10K | -585.60K | 321.04K | 200.33K | 7.12M | -11.01K | 4.40M | 10.00K |
| Cost & Expenses | 1.58M | 5.21M | 2.62M | 4.64M | 2.98M | 532.77K | 6.63K | 1.00M | 11.46M | 2.03M | 80.31K | 89.57K | 97.10K | -585.60K | 321.04K | 200.33K | 7.12M | -11.01K | 4.89M | 10.00K |
| Interest Income | 0.00 | 2.29K | 1.51K | 2.29K | 4.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.70M | 2.29M | 1.51M | 2.29M | 4.47M | 2.14M | 0.00 | 423.00 | 2.72K | 3.95K | 14.10K | 8.50K | 2.56K | 10.20K | 4.87K | 1.26K | 4.25K | 1.40K | -460.00K | -30.00K |
| Depreciation & Amortization | 127.85K | 294.93K | 2.71K | 128.51K | 129.04K | 532.77K | 6.63K | 12.03K | 12.03K | 3.02K | 0.00 | 0.00 | 0.00 | 0.00 | -207.30K | 0.00 | -7.23M | -87.13K | 990.00K | -60.00K |
| EBITDA | -1.45M | -4.91M | -2.61M | -17.47M | -2.85M | -954.26K | -6.63K | -992.86K | -11.64M | -3.97M | -80.31K | -89.57K | -97.10K | 585.60K | -93.56K | -200.33K | -14.35M | -76.12K | -3.27M | -70.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -680.65% | 0.00% |
| Operating Income | -1.58M | -5.21M | -2.99M | -14.49M | -15.98M | -954.32K | -6.63K | -1.00M | -11.46M | -3.97M | -80.31K | -89.57K | -97.10K | 585.60K | 113.74K | -200.33K | -7.12M | 11.01K | -4.27M | -10.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -688.71% | 0.00% |
| Total Other Income/Expenses | 5.27M | -3.32M | -5.84M | -5.40M | -4.47M | -2.14M | 0.00 | 3.64K | -90.47K | -1.97M | -14.10K | -8.50K | -2.56K | -10.20K | -4.88K | -1.26K | 14.23M | -1.40K | -480.00K | -30.00K |
| Income Before Tax | 3.69M | -8.53M | -8.83M | -19.89M | -20.45M | -3.09M | -6.63K | -1.00M | -11.74M | -3.98M | -94.41K | -98.07K | -99.66K | 575.40K | 108.86K | -201.59K | 7.11M | 9.61K | -4.75M | -40.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -766.13% | 0.00% |
| Income Tax Expense | 0.00 | 2.69M | 1.51M | 2.29M | 4.47M | 2.14M | -6.64K | 423.00 | 2.72K | 1.95M | 0.00 | 0.00 | 0.00 | 0.00 | 212.18K | 0.00 | -7.00M | 88.54K | -940.00K | 0.00 |
| Net Income | 3.69M | -8.53M | -10.34M | -22.18M | -24.92M | -3.09M | -6.63K | -1.00M | -11.74M | -3.98M | -94.41K | -98.07K | -99.66K | 575.40K | 108.86K | -201.59K | 7.11M | 9.61K | -4.75M | -40.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -766.13% | 0.00% |
| EPS | 0.01 | -0.04 | -0.14 | -0.55 | -0.80 | -0.17 | 0.00 | -0.06 | -0.77 | -0.36 | -0.04 | -0.04 | -0.04 | 0.24 | 0.05 | -0.09 | 3.45 | 0.01 | -1.54 | -0.02 |
| EPS Diluted | 0.01 | -0.04 | -0.14 | -0.55 | -0.80 | -0.17 | 0.00 | -0.06 | -0.77 | -0.36 | -0.04 | -0.04 | -0.04 | 0.24 | 0.05 | -0.09 | 3.45 | 0.01 | -1.54 | -0.02 |
| Weighted Avg Shares Out | 308.94M | 211.04M | 74.69M | 40.70M | 31.17M | 17.96M | 17.96M | 17.96M | 15.34M | 11.07M | 2.38M | 2.38M | 2.38M | 2.36M | 2.36M | 2.29M | 2.06M | 831.86K | 3.08M | 2.08M |
| Weighted Avg Shares Out (Dil) | 308.94M | 211.04M | 74.69M | 40.70M | 31.17M | 17.96M | 17.96M | 17.96M | 15.34M | 11.07M | 2.38M | 2.38M | 2.38M | 2.36M | 2.36M | 2.29M | 2.06M | 831.86K | 3.08M | 2.08M |
CannaPharmaRx Achieves IMC-GAP and GACP Certifications Completing a Significant Milestone Towards Revenue Acceleration
CALGARY, AB / ACCESSWIRE / February 23, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that the company has successfully obtained our IMC-GAP (Good Agricultural Practices) and GACP (Good Agricultural...
CannaPharmaRx Finalizes Multi-Million Dollar Israeli Supply Agreement with Cantek
CALGARY, AB / ACCESSWIRE / February 16, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has entered into a strategic Supply Agreement (the "Agreement") with Cantek Holdings ("Cantek"),...
CannaPharmaRx CEO Provides Annual Update Message
CALGARY, AB / ACCESSWIRE / February 15, 2024 / Cannapharmarx, Inc. Dear Fellow Shareholders, We are paving the way for a remarkable year capitalizing on the solid foundation achieved last year. 2023 was an exciting and pivotal year for CannaPharmaRx...
CannaPharmaRx Expands Board of Directors
CALGARY, AB / ACCESSWIRE / August 25, 2023 / CannaPharmaRx, Inc. (OTC EXPERT:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has expanded its Board of Directors from three seats to five. The Board...
CannaPharmaRX, Inc. Closes Sale of Hanover Facility for $2,000,000 CAD
CALGARY, AB / ACCESSWIRE / July 13, 2021 / CannapharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities in Canada, announced today the sale of its Hanover, Ontario facility for $2,000,000 CAD. The Hanover facility...
CannaPharmaRx Comments on Stock Promotion Flag
CALGARY, AB / ACCESSWIRE / June 24, 2021 / CannaPharmaRx, Inc. (OTC PINK:CPMD) a future leader in ultramodern, highly efficient cannabis production facilities in Canada, announced that it has been brought to its attention that a Third Party has issued...
CannaPharmaRX, Inc. Signs Agreement with Israeli Group K&K Consulting
Agreement Provides Exposure to Israeli Medicinal Cannabis Market CALGARY, AB / ACCESSWIRE / June 16, 2021 / CannapharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities in Canada, announced today it has formally executed an...
CannapharmaRx, Inc. Announces Changes to its Board of Directors
CALGARY, AB / ACCESSWIRE / March 25, 2021 / CannapharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities in Canada, announced today that it has consolidated its Board of Directors to include a team more...
CannapharmaRx, Inc. Announces Non-Dilutive Commitment Financing for Assets and Facilities Located in Cremona, AB
CALGARY, AB / ACCESSWIRE / January 19, 2021 / CannapharmaRx, Inc. (OTC PINK:CPMD) a future leader in ultramodern, highly efficient cannabis production facilities in Canada announced today that it has secured a commitment letter for twelve million dollars ($12,000,000) for...
CannapharmaRx, Inc. Announces the Acceptance of Its Offer to Purchase Assets and Facilities Located in Cremona, AB
CALGARY, AB / ACCESSWIRE / January 12, 2021 / CannapharmaRx, Inc. (OTC PINK:CPMD) a future leader in ultramodern, highly efficient cannabis production facilities in Canada announced today that it has entered into a definitive agreement to purchase certain assets including...
Source: https://incomestatements.info
Category: Stock Reports